177 related articles for article (PubMed ID: 11786197)
1. Processing of neuropeptide Y, galanin, and somatostatin in the cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia.
Nilsson CL; Brinkmalm A; Minthon L; Blennow K; Ekman R
Peptides; 2001 Dec; 22(12):2105-12. PubMed ID: 11786197
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin and neuropeptide Y in cerebrospinal fluid: correlations with severity of disease and clinical signs in Alzheimer's disease and frontotemporal dementia.
Minthon L; Edvinsson L; Gustafson L
Dement Geriatr Cogn Disord; 1997; 8(4):232-9. PubMed ID: 9213068
[TBL] [Abstract][Full Text] [Related]
3. Processing of neuropeptide Y and somatostatin in human cerebrospinal fluid as monitored by radioimmunoassay and mass spectrometry.
Nilsson C; Westman A; Blennow K; Ekman R
Peptides; 1998; 19(7):1137-46. PubMed ID: 9786162
[TBL] [Abstract][Full Text] [Related]
4. Correlation between clinical characteristics and cerebrospinal fluid neuropeptide Y levels in dementia of the Alzheimer type and frontotemporal dementia.
Minthon L; Edvinsson L; Gustafson L
Alzheimer Dis Assoc Disord; 1996; 10(4):197-203. PubMed ID: 8939279
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid somatostatin and neuropeptide Y. Concentrations in aging and in dementia of the Alzheimer type with and without extrapyramidal signs.
Atack JR; Beal MF; May C; Kaye JA; Mazurek MF; Kay AD; Rapoport SI
Arch Neurol; 1988 Mar; 45(3):269-74. PubMed ID: 2893600
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid neuropeptides in Alzheimer's disease and vascular dementia.
Heilig M; Sjögren M; Blennow K; Ekman R; Wallin A
Biol Psychiatry; 1995 Aug; 38(4):210-6. PubMed ID: 8547442
[TBL] [Abstract][Full Text] [Related]
7. Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia.
Diamandis EP; Scorilas A; Kishi T; Blennow K; Luo LY; Soosaipillai A; Rademaker AW; Sjogren M
Clin Biochem; 2004 Mar; 37(3):230-7. PubMed ID: 14972646
[TBL] [Abstract][Full Text] [Related]
8. Neuropeptide levels in Alzheimer's disease and dementia with frontotemporal degeneration.
Minthon L; Edvinsson L; Ekman R; Gustafson L
J Neural Transm Suppl; 1990; 30():57-67. PubMed ID: 1975266
[TBL] [Abstract][Full Text] [Related]
9. Neuropeptide Y (NPY) in cerebrospinal fluid from patients with Huntington's Disease: increased NPY levels and differential degradation of the NPY1-30 fragment.
Wagner L; Björkqvist M; Lundh SH; Wolf R; Börgel A; Schlenzig D; Ludwig HH; Rahfeld JU; Leavitt B; Demuth HU; Petersén Å; von Hörsten S
J Neurochem; 2016 Jun; 137(5):820-37. PubMed ID: 27016395
[TBL] [Abstract][Full Text] [Related]
10. Shunt related changes in somatostatin, neuropeptide Y, and corticotropin releasing factor concentrations in patients with normal pressure hydrocephalus.
Poca MA; Mataró M; Sahuquillo J; Catalán R; Ibañez J; Galard R
J Neurol Neurosurg Psychiatry; 2001 Mar; 70(3):298-304. PubMed ID: 11181849
[TBL] [Abstract][Full Text] [Related]
11. Novel neuropeptide Y processing in human cerebrospinal fluid from depressed patients.
Ekman R; Juhasz P; Heilig M; Agren H; Costello CE
Peptides; 1996; 17(7):1107-11. PubMed ID: 8959743
[TBL] [Abstract][Full Text] [Related]
12. Galanin and α-MSH autoantibodies in cerebrospinal fluid of patients with Alzheimer's disease.
Costa A; Bini P; Hamze-Sinno M; Moglia A; Franciotta D; Sinforiani E; Ravaglia S; Bole-Feysot C; Hökfelt T; Déchelotte P; Fetissov SO
J Neuroimmunol; 2011 Dec; 240-241():114-20. PubMed ID: 22078238
[TBL] [Abstract][Full Text] [Related]
13. CSF levels of a set of neurotrophic factors (brain-derived neurotrophic factor, nerve growth factor) and neuropeptides (neuropeptide Y, galanin) in epileptic children.
Tekgul H; Serin HM; Simsek E; Kanmaz S; Gazeteci H; Azarsiz E; Ozgur S; Yilmaz S; Aktan G; Gokben S
J Clin Neurosci; 2020 Jun; 76():41-45. PubMed ID: 32327377
[TBL] [Abstract][Full Text] [Related]
14. Neuropeptides in cerebrospinal fluid of patients with Alzheimer's disease and dementia with frontotemporal lobe degeneration.
Edvinsson L; Minthon L; Ekman R; Gustafson L
Dementia; 1993; 4(3-4):167-71. PubMed ID: 8401787
[TBL] [Abstract][Full Text] [Related]
15. Neuropeptides in cerebrospinal fluid in normal-pressure hydrocephalus and dementia.
Wikkelsö C; Ekman R; Westergren I; Johansson B
Eur Neurol; 1991; 31(2):88-93. PubMed ID: 1675171
[TBL] [Abstract][Full Text] [Related]
16. Relationship of interleukin-1 beta and beta 2-microglobulin with neuropeptides in cerebrospinal fluid of patients with dementia of the Alzheimer type.
Martinez M; Frank A; Hernanz A
J Neuroimmunol; 1993; 48(2):235-40. PubMed ID: 7693756
[TBL] [Abstract][Full Text] [Related]
17. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
[TBL] [Abstract][Full Text] [Related]
18. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Trenkwalder C; Otto M; Stiens G; Rüther E; Kornhuber J; Wiltfang J
Mol Psychiatry; 2007 Jul; 12(7):671-80. PubMed ID: 17339876
[TBL] [Abstract][Full Text] [Related]
19. TAU haplotype and the Saitohin Q7R gene polymorphism do not influence CSF Tau in Alzheimer's disease and are not associated with frontotemporal dementia or Parkinson's disease.
Johansson A; Zetterberg H; Håkansson A; Nissbrandt H; Blennow K
Neurodegener Dis; 2005; 2(1):28-35. PubMed ID: 16909000
[TBL] [Abstract][Full Text] [Related]
20. The Effects of Levetiracetam on Cerebrospinal Fluid and Plasma NPY and GAL, and on the Components of Stress Response System, hs-CRP, and S100B Protein in Serum of Patients with Refractory Epilepsy.
Chen W; Tan Y; Ge Y; Chen Y; Liu X
Cell Biochem Biophys; 2015 Nov; 73(2):489-494. PubMed ID: 27352343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
